Ampreloxetine Misses Endpoint in Second Neurogenic Orthostatic Hypotension Trial
The phase 3 REDWOOD study included patients aged 30 years and older with primary autonomic failures and symptomatic neurogenic orthostatic hypotension.
Orthostatic Hypotension
Drugs Prescribed Widely for Common Conditions Linked to Orthostatic Hypotension
The meta-analysis included 69 RCTs with a total of 27,079 patients.
Study Evaluating Ampreloxetine for Neurogenic Orthostatic Hypotension Misses Endpoint
The phase 3 study was evaluating the efficacy and safety of ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension in patients 30 years of age and older.
Orthostatic Hypotension and Dementia: What’s the Link?
Middle-aged adults found 40 percent more likely to develop dementia over time
